Market Place
Sourcing Support
Sanofi`s Biologic Soliqua Receives Suppl Approval in US
01 Nov 2024 //
FDA
GoodRx to offer Sanofi`s insulin injection for only $35
19 Oct 2023 //
REUTERS
Mylan`s Biologic Semglee(Insulin Glargine) Receives Approval in the U.S.
30 May 2023 //
FDA
Sanofi to cut US price of its most-prescribed insulin by 78%
17 Mar 2023 //
REUTERS
Glooko, Sanofi Partner for SoloStar Pen Connectivity with New Device SoloSmart
23 Feb 2023 //
CONTRACT PHARMA
FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar
19 Nov 2022 //
BIOPHARMADIVE
Lilly wins FDA approval for second interchangeable insulin biosimilar
18 Nov 2022 //
ENDPTS
Eli Lilly`s Biologic Rezvoglar (Glargine) Receives Approval in the U.S.
16 Nov 2022 //
FDA
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
20 Sep 2022 //
PINK SHEET
BIOCORP announces the CE marking of SoloSmart®, an accessory medical device
19 Sep 2022 //
BUSINESSWIRE
Skylight Health Announces Series A Preferred Stock Cash Dividend
16 Sep 2022 //
GLOBENEWSWIRE
Diabetes, patented TB, HIV drugs enter essential list
13 Sep 2022 //
ECONOMICTIMES
Eris Lifesciences enters licensing deal with Biocon for insulin glargine
05 Aug 2022 //
ECONOMIC TIMES
Enforcement Report - Week of August 3, 2022
03 Aug 2022 //
FDA
CivicaScript Announces Launch of its First Product
03 Aug 2022 //
BUSINESSWIRE
Enforcement Report - Week of May 4, 2022
04 May 2022 //
FDA
Viatris is pulling another insulin batch following a label snafu
14 Apr 2022 //
FIERCEPHARMA
LANNETT INITIATES PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
29 Mar 2022 //
PRNEWSWIRE
Lannett says FDA completes review of IND application for Insulin Glargine
21 Jan 2022 //
PRNEWSWIRE
Viatris` Mylan recalled one lot of non-interchangeable Semglee
21 Jan 2022 //
FIERCEPHARMA
FDA Approves Second Biosimilar Insulin Product, Rezvoglar
20 Dec 2021 //
PRACTICEUPDATE
Sandoz Reviews Insulin Access, Cost, and Biosimilar Potential
10 Dec 2021 //
CENTERFORBIOSIMILAR
Biocon-Viatris, AstraZeneca, Huhai and more—Fierce Pharma Asia
19 Nov 2021 //
FIERCEPHARMA
Biocon Biologics, Viatris launch biosimilar insulin glargine in US
17 Nov 2021 //
MONEYCONTROL
Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever
04 Nov 2021 //
BIOCON
Prime Therapeutics backs first interchangeable insulin biosimilar Semglee®
03 Nov 2021 //
PRIMETHERAPEUTICS
Tirzepatide maintains AC1 and weight control in type 2 diabetes patients
21 Oct 2021 //
EUROPEANPHARMACEUTICALREVIEW
Lilly`s Longest Diabetes Drug Trial Lowers A1C and Increases Weight Loss
19 Oct 2021 //
BIOSPACE
FDA Approvals Roundup: Semglee, Saphnelo, Uptravi
04 Aug 2021 //
RAPS
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP)
02 Jul 2021 //
PR NEWSWIRE
New data on the insulins Aspart (GL-ASP), Lispro (GL-LIS) and Glargine (GL-GLA)
02 Jul 2021 //
PR NEWSWIRE
Glargine launch in US opens up a huge opportunity for Biocon
31 Aug 2020 //
ECONOMIC TIMES
Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine).
31 Aug 2020 //
PRNEWSWIRE
Mylan Pharms`s insulin glargine Receives Supplemental Approval in US
16 Jun 2020 //
FDA
Biocon and Mylan receive US FDA approval for Semglee, an insulin glargine
12 Jun 2020 //
EXPRESS PHARMA
Biocon gets US FDA nod to launch insulin glargine
11 Jun 2020 //
ECONOMICTIMES
Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine
10 Jun 2020 //
PRNEWSWIRE
PTAB Issues Final Written Decisions Finding Most Claims of Sanofi’s Lantus
04 Jun 2020 //
LAW360
Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition
24 Feb 2020 //
RAPS
Biocon`s Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
24 Feb 2020 //
PRESS RELEASE
VISTA Eye Specialist brings vision correction to new level
09 Jan 2020 //
BIOSPECTRUM ASIA
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
20 Dec 2019 //
FIERCE PHARMA
FDA Approves Sanofi`s Toujeo to Treat Childhood Type 1 Diabetes
27 Nov 2019 //
BIO SPACE
Positive results Ph3 trial for Toujeo® children and adolescents type 1 diabetes
04 Nov 2019 //
PR NEWSWIRE
What`s at stake for pharma in Pelosi`s pricing plan? Megabillions
12 Sep 2019 //
FIERCE PHARMA
Novo Nordisk rolls out authorized insulin generics
07 Sep 2019 //
FIERCEPHARMA
Mylan`s Lantus copy derailed in U.S. again by manufacturing ills
03 Sep 2019 //
FIERCE PHARMA
USFDA issues response letter for new drug application for insulin glargine: Biocon
02 Sep 2019 //
ECONOMIC TIMES
Biocon Malaysia unit receives EU GMP certification
22 Aug 2019 //
BIOSPECTRUMASIA
Biocon`s Malaysia arm gets good manufacturing certificate from EU regulator
21 Aug 2019 //
BUSINESS-STANDARD
Biocon`s Malaysia insulins facility gets approval of European drug regulator
21 Aug 2019 //
MONEYCONTROL
USFDA issues 12 observations for 3 Biocon units in Malaysia
09 Jul 2019 //
ECONOMIC TIMES
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
08 Jul 2019 //
FIERCE PHARMA
